What's Going On With Merck Stock On Friday?
What's Going On With Merck Stock On Friday?
On Thursday, the U.S. Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) unanimously voted to recommend Merck & Co Inc's (NYSE:MRK) Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) for adults 65 years of age and older. It is also commonly known as the pneumonia vaccine.
周四，美国疾病控制与预防中心免疫实践咨询委员会一致投票推荐默沙东公司（纽交所代码：MRK）Capvaxive（肺炎球菌21价结合疫苗）推荐给65岁以上的成年人，也常被称为肺炎疫苗。
Specifically, the ACIP voted to recommend a single dose of Capvaxive for:
具体来说，ACIP建议为以下这些人推荐单剂量的Capvaxive：
- Adults 65 years and older who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown.
- Adults 19-64 years of age with certain underlying medical conditions or other risk factors who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown.
- Adults 19 years and older who have started their pneumococcal vaccine series with PCV13 (pneumococcal 13-valent conjugate vaccine) but have not received all recommended PPSV23 (pneumococcal 23-valent polysaccharide vaccine) doses.
- 年龄在65岁及以上的成年人，未曾接种肺炎球菌结合疫苗或疫苗接种史未知的人。
- 19-64岁、具有特定潜在医学条件或其他风险因素、未曾接种肺炎球菌结合疫苗或疫苗接种史未知的成年人。
- 已开始接种肺炎球菌疫苗系列，使用了PCV13（肺炎球菌13价结合疫苗），但未接受所有建议的PPSV23（肺炎球菌23价多糖疫苗）剂量的19岁及以上成年人。
Additionally, shared clinical decision-making is recommended regarding the use of a supplemental dose of Capvaxive for adults 65 years and older who have completed their vaccine series with both PCV13 and PPSV23.
此外，对于年龄在65岁及以上、已完成PCV13和PPSV23疫苗系列接种的成年人，建议共同进行临床决策，以使用Capvaxive的补充剂量。
Friday, Merck announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommended the approval of Winrevair (sotatercept), in combination with other pulmonary arterial hypertension (PAH) therapies for adult PAH patients with World Health Organization Functional Class II to III, to improve exercise capacity.
默沙东周五宣布，欧洲药品管理局人用药品委员会（CHMP）推荐批准Winrevair（Sotatercept），联合其他肺动脉高压（PAH）疗法治疗世界卫生组织功能分级为II到III级的成年PAH患者，以提高运动能力。
The European Commission (EC) will now review the CHMP recommendation. The EC's decision on Winrevair's marketing authorization application is expected in the third quarter of 2024.
欧洲委员会（EC）将现在评审CHMP的建议。预计EC将于2024年第三季度就Winrevair的上市许可申请作出决定。
The CHMP recommendation is based on data from the Phase 3 STELLAR trial of Winrevair on top of background PAH therapy compared to background therapy alone.
CHMP的建议基于Winrevair的III期STELLAR试验数据，该试验对背景PAH疗法加上Winrevair与背景疗法单独相比进行了比较。
Winrevair demonstrated a statistically significant and clinically meaningful improvement in the 6-minute walk distance, the study's primary endpoint, and on multiple important secondary outcome measures, including reducing the risk of death from any cause or PAH clinical worsening events.
Winrevair在6分钟步行距离以及多个重要的二级终点指标方面表现出了具有统计学意义的临床意义，并减少了任何原因或PAH临床恶化事件的死亡风险。
Also Read: FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug.
还阅读：FDA拒绝批准默沙东与第一三共合作的肺癌药物。
Price Action: MRK shares were trading higher by 0.13% at $129.99 premarket at the last check on Friday.
截至周五，MRK股价于盘前交易时上涨了0.13%，报129.99美元。
Photo via Unsplash
照片来自Unsplash